LivaNova (NASDAQ:LIVN) Releases FY 2025 Earnings Guidance

LivaNova (NASDAQ:LIVN) updated its FY 2025 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 3.650-3.750 for the period, compared to the consensus estimate of 3.630. The company issued revenue guidance of $1.3 billion-$1.3 billion, compared to the consensus revenue estimate of $1.3 billion.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Needham & Company LLC reiterated a “buy” rating and issued a $75.00 price target on shares of LivaNova in a research note on Tuesday, January 28th. StockNews.com upgraded LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 14th. Robert W. Baird increased their price target on LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. Finally, Mizuho cut their price target on LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a research note on Thursday, October 31st. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $69.17.

LivaNova Trading Up 4.3 %

Shares of LivaNova stock opened at $49.50 on Tuesday. The firm has a market cap of $2.69 billion, a price-to-earnings ratio of 117.86 and a beta of 1.00. The business has a 50-day moving average price of $47.94 and a 200-day moving average price of $49.64. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. LivaNova has a twelve month low of $43.15 and a twelve month high of $64.47.

Insider Activity at LivaNova

In related news, Director Francesco Bianchi sold 1,250 shares of the stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total value of $63,737.50. Following the completion of the transaction, the director now owns 7,522 shares of the company’s stock, valued at approximately $383,546.78. This trade represents a 14.25 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.27% of the stock is owned by insiders.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.